Navigation Links
Xanthus Presents Novel Approach for Autoimmune Disease Reversal,with Symadex

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 3, 2007 - Xanthus Pharmaceuticals, Inc today presented data demonstrating that Symadex(TM) reversed the clinical and pathological signs of chronic disease in an animal model for multiple sclerosis. The presentation was made by Stephen J. Karlik, Ph.D., Professor of Diagnostic Radiology at the University of Western Ontario, London, Ontario, together with researchers from Xanthus in a poster session at the 59th American Academy of Neurology Meeting in Boston, MA.

Using a model of experimental autoimmune encephalomyelitis (EAE) that is designed to represent multiple sclerosis, Dr. Karlik tested Symadex for its effect on both acute and chronic disease. In the acute EAE model, animals treated with Symadex substantially recovered while in control animals the disease symptoms and damage remained unchanged. In chronic EAE disease models, clinical and pathological disease reversal and tissue recovery were observed with Symadex treatment. At the same time, Symadex did not affect circulating immune cell numbers, suggesting that it does not act as a general immunosuppressant.

"Symadex' ability to reverse chronic autoimmune disease in this animal model is notable. The study results suggest this activity may result from inhibiting macrophage function rather than inhibiting T cell function. This mechanism is novel in my experience," said Dr. Karlik.

"We now have a significant body of promising preclinical data supporting the use of Symadex in multiple autoimmune indications. We believe this represents a strong partnering opportunity for our Company, and we are preparing to initiate a human proof-of-principle trial with Symadex in autoimmune disease," stated Richard T. Dean, Ph.D., Xanthus' Chief Executive Officer.

About Symadex(TM)

Symadex (formerly C-1311) is the lead compound from a new series of agents, the imidazoacridinones, which have been shown to be po
'"/>




Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:9/30/2014)... LONDON , Sept. 30, 2014 ... market for molecular imaging informatics solutions including nuclear ... fusion and comparison. The study assesses the size ... between 2010 and 2013, and projects future growth ... well as the dynamics taking place in the ...
(Date:9/30/2014)... , Sept. 30, 2014  Decision Resources Group finds ... Brazil , Russia ... China (BRIC) will see robust expansion as ... favored over surgical procedures. Although revenues will be somewhat ... challenges, prolonged device approval times and demand for low-cost ...
(Date:9/30/2014)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) ... development and commercialization of prescription ophthalmic pharmaceuticals, announced today ... Hercules Technology Growth Capital, Inc. (NYSE: HTGC ... advance under the Loan and Security Agreement that Alimera,s ... Alimera Sciences Limited, entered into with Hercules in April ...
Breaking Medicine Technology:Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2
... CAMBRIDGE, Mass., Dec. 22, 2011  Inspiration Biopharmaceuticals, Inc. ... the development and commercialization of new treatment options ... Company has expanded its leadership team with four ... Inspiration as Chief Medical Officer; Daniel Regan as ...
... Dec. 22, 2011  PTC Therapeutics, Inc. (PTC) today ... Drug Discovery (SDD) Award from the Wellcome Trust ... target life-threatening infections caused by multidrug-resistant (MDR) Gram-negative ... Award from the Wellcome Trust to support its ...
Cached Medicine Technology:Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires 2Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires 3Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires 4Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires 5PTC Therapeutics' Antibacterial Program Receives $5 Million Award from the Wellcome Trust 2
(Date:9/30/2014)... Children conceived either less than one year or more than ... at increased risk for autism, a new study suggests. ... agree that the research can,t prove that birth spacing has ... important that parents understand that the odds for autism are ... far apart," said outside expert Dr. Andrew Adesman. He is ...
(Date:9/30/2014)... damaging "brain tsunamis" in injured patients without opening ... reality, thanks to pioneering research at the University ... team, led by Jed Hartings, PhD, research associate ... UC College of Medicine, has shown that spreading ... like tsunami wavescan be measured by the placement ...
(Date:9/30/2014)... lung cancer, breast cancer is the leading cause of ... Society. That,s why so many medical professionals encourage women ... at best: only a minority of suspicious mammograms actually ... lots of needless worry for women and their familiesnot ... tests, including ultrasounds and biopsies. , Recently, a ...
(Date:9/30/2014)... Legislation passed in 2003 to slow the spiraling ... to treat Medicare patients has had no meaningful impact ... researchers in the Journal of Clinical Oncology ... outpatient chemotherapy to treat colorectal and lung cancers, and ... prescribe those drugs following the implementation of the recent ...
(Date:9/30/2014)... NJ (PRWEB) September 30, 2014 ... and wellness, is opening another new medical specialty practice ... IMA Cardiology will be located within the ... Ziad Abbud and Dr. Isaac Tawfik of American Heart ... N.J. The new practice will offer Integrated Medicine Alliance ...
Breaking Medicine News(10 mins):Health News:Spacing Between Sibling Births Tied to Autism Risk in Study 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:'Virtual breast' could improve cancer detection 2Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2
... say finding could be key to new disease-fighting therapies ... on mice suggests inhibiting a protein that allows certain ... to cancer-fighting treatments. , A study by Pierre Sonveaux ... found that tumor cells use different fuel sources depending ...
... A team of researchers at Duke University Medical Center and ... acid is an important energy source for tumor cells. In ... most hard-to-kill, dangerous tumor cells by preventing them from delivering ... than 50 years that low-oxygen, or hypoxic, cells cause resistance ...
... MORRISTOWN, N.J., Nov. 20 /PRNewswire/ Bayer HealthCare,has donated hundreds ... New Jersey,(CFBNJ) in response to an urgent call from ... supplies at the state,s food banks. , ... , Mary Lou Panzano, director, US Internal ...
... cancer patients who underwent a mastectomy who undergo ... reconstruction provides fewer long-term complications and better cosmetic ... to a study in the November issue of ... the official journal of the American Society for ...
... Alzheimer,s relatives at risk for hospital visits of their own ... providing care for a loved one with Alzheimer,s results in ... room or hospital visit every six months, says an Indiana ... care of an Alzheimer,s patient is difficult, but the Indiana ...
... Centre Finalizes Construction Plan and Begins Marketing; John Strong, ... Inc., to Lead Sales and Marketing Efforts , ... The world,s first permanent international healthcare marketplace and ... the key players driving the project said today, as ...
Cached Medicine News:Health News:Lactic acid found to fuel tumors 2Health News:Bayer HealthCare Donates Hundreds of Food Items to Community Food Bank of New Jersey in Response to Governor's Plea to Help the State's Population in Need 2Health News:Type of breast reconstruction impacts radiation therapy outcomes 2Health News:When the Caregiver Becomes the Patient 2Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 2Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 3Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 4Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 5
The 45 PSI SuperSportNeb provides superior performance that translates to shorter treatment times. Like the SportNeb, it is constructed with die-cast aluminum compressor components for consistent rel...
... PulmoAide Compact Compressor provides effective therapy at an ... therapy at home or on the go and ... the same reliable operation you have come to ... Compressor is the perfect solution for those patients ...
The 16 liter Laparoscopy Insufflator combines high safety and precise pressure control with simple operation....
Stryker's 40-liter insufflator provides superior performance with unprecedented safety and reliability....
Medicine Products: